Leveraging his seven years of extensive commercialisation experience in the biotechnology sector, Terry oversees the operations of Gertrude Biomedical. He is currently aiding in the development of novel SOX18 inhibitors for oncology indications, having previously advanced small molecules to clinical trials. Terry is commercially focused and facilitates operational business development by providing strategic management and administrative leadership to Gertrude Biomedical. His project management role includes planning and implementing financial management and operational activities to contribute to the Company’s success.